Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3565-3574

  Domingo, C ^a   Gadea, I ^b   Pardeiro, M ^b   Castilla, C ^c   Fernandez S ^a   Fernandez Clua M A ^b   De La Cruz Troca, J J ^a   Punzon C ^a   Soriano, F ^b   Fresno, M ^a   Tabares E ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Fundación Jiménez Díaz   (Spain)

^c Fund Jiménez Díaz   (Spain)

Author keywords

gB2; gD2 DNA immunization

Indexed keywords

CHIMERIC PROTEIN; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN B; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G ANTIBODY; PLASMID DNA; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; GENETIC CODE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL; VAGINITIS;

EID: 10744221426     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00423-7     Document Type: Article

References (69)

1. Corey L., Spear P.G. Infections with herpes simplex. N. Engl. J. Med. 314:1986;749-757.
2. Spear PG. Glycoproteins specified by herpes simplex virus. In: Roizman B, Lopez C, editors. The herpesviruses. New York: Plenum Press; 1985. p. 315-56.
3. Manservigi R., Spear P.G., Buchan A. Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 74:1977;3913-3917.
4. Sarmiento M., Haffey M., Spear P.G. Membrane proteins specified by herpes simplex virus. III. Role of glycoprotein VP7 (B2) in virion infectivity. J. Virol. 29:1979;1149-1158.
5. Cai W., Gu B., Person R. Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion. J. Virol. 62:1988;2596-2604.
6. Ligas M.W., Johnson D.C. A herpes simplex virus mutant in which glycoprotein D sequences are replaced by β-galactosidase sequences binds to but is unable to penetrate into cell. J. Virol. 62:1988;1486-1494.
7. Bernstein D.I., Loo L.S., Kohl S. Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection. Antiviral Res. 10:1988;279-284.
8. Long D., Madara T.J., Ponce de Leon M., Cohen G.H., Montgomery P.C., Eisenberg R.J. Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect. Immun. 37:1984;761-764.
9. Nesburn A.B., Burke R.L., Ghiasi H., Slanina S., Bahri S., Wechsler S.L. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J. Virol. 68:1994;5084-5092.
10. Handler C.G., Eisenberg R.J., Cohen G.H. Oligomeric structure of glycoproteins in herpes simplex virus type 1. J. Virol. 70:1996;6067-6075.
11. Handler C.G., Cohen G.H., Eisenberg R.J. Cross-linking of glycoprotein oligomers during herpes simplex virus type 1 entry. J. Virol. 70:1996;6076-6082.
12. Ghiasi H., Kaiwar R., Nesburn A.B., Slanina S., Wechsler S.L. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, and gI): comparative protection against lethal challenge in mice. J. Virol. 68:1994;2126-2128.
13. Meignier B., Jourdier T.M., Norrild B., Pereira L., Roizman B. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J. Infect. Dis. 155:1987;921-930.
14. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:1987;914-920.
15. Balachandran N., Bachetti S., Rawls W.E. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect. Immun. 37:1982;1132-1137.
16. Corey L., Langenberg A.G.M., Ashley R.et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection. Two randomized controlled trials. JAMA. 282:1999;331-340.
17. Langenberg A.G.M., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L.et al. A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann. Intern. Med. 122:1995;889-898.
18. Straus S.E., Wald A., Kost R.G.et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176:1997;1129-1134.
19. Harandi A.M., Svennerholm B., Holmgren J., Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptative immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:2001;845-853.
20. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1998;1500-1508.
21. Manickan E., Rouse R.J.D., Yu Z., Wire W.S., Rouse B.T. Genetic immunization against herpes simplex virus: protection is mediated by CD4+ T lymphocytes. J. Immunol. 155:1995;259-265.
22. Milligan G.N., Bernstein D.I. Interferon-γ enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology. 229:1997;259-268.
23. Parr M.B., Parr E.L. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J. Virol. 72:1998;2677-2685.
24. Schmid D.S., Rouse B.T. The role of T cell immunity in control of herpes simplex virus. Curr. Top. Microbiol. Immunol. 179:1992;57-69.
25. Simmons A., Nash A.A. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J. Virol. 52:1984;816-821.
26. Sin J., Kim J.J., Boyer J.D., Ciccarelli R.B., Higgins T.J., Weiner D.B. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol. 73:1999;501-509.
27. Bourne N., Stanberry L.R., Bernstein D.I., Lew D. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173:1996;800-807.
28. Gebhard J.R., Zhu J., Cao X., Minnick J., Araneo B.A. DNA immunization utilizing a herpes simplex type 2 myogenic DNA vaccine protects mice from mortality and prevents genital herpes. Vaccine. 18:2000;1837-1846.
29. Kriesel J.D., Spruance S.L., Daynes R.A., Araneo B.A. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease. J. Infect. Dis. 173:1996;536-541.
30. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:1997;3138-3145.
31. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. Immunisation with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11414-11420.
32. Nass P.H., Elkins K.L., Weir J.P. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. J. Infect. Dis. 178:1998;611-617.
33. Rogers J.V., Hull B.E., Fink P.S., Chiou H.C., Bigley N.J. Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver. Vaccine. 18:2000;1522-1530.
34. Wolff J.A., Malone R.W., Williams P., Chong W., Ascadi G., Jani A.et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
35. Hasset D.E., Whitton J.L. DNA immunization. Trends Microbiol. 4:1996;307-312.
36. Liu M.A., Ulmer J.B. Gene-based vaccines. Mol. Ther. 1:2000;497-500.
37. Otten G.R., Doe B., Schaefer M., Chen M., Selby M.J., Goldbeck C.et al. Relative potency of cellular and humoral immune responses induced by DNA vaccination. Intervirology. 43:2000;227-232.
38. Fresno M., Kopf M., Rivas L. Cytokines and infectious diseases. Immunol. Today. 18:1997;56-58.
39. Ulmer J.B., Donnelly J.J., Parker S.E.et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
40. Braun R., Babiuk L.A., Van Drunen Littel-van den Hurk S. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J. Gen. Virol. 79:1998;2965-2970.
41. Cardoso A.I., Sixt N., Vallier A., Fayolle J., Buckland R., Wild T.F. Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. J. Virol. 72:1998;2516-2518.
42. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70:1994;369-380.
43. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
44. Stuve L.L., Brown-Shimer S., Pachl C., Najarian R., Dina D., Burke R.L. Structure and expresión of the herpes simples virus type 2 glycoprotein gB gene. J. Virol. 61:1987;326-335.
45. Watson R.J. DNA sequense of the herpes simples virus type 2 glycoprotein D gene. Gene. 26:1983;307-312.
46. Escribano J.M., Tabarés E. Proteins specified by African swine fever virus. V. Identification of immediate early. Arch. Virol. 92:1987;221-232.
47. Tabarés E., Marcotegui M.A., Fernández M., Sánchez Botija C. Proteins specified by African swine fever virus. I. Analysis of the structural proteins and antigenic properties. Arch. Virol. 66:1980;49-59.
48. Higgins T.J., Herold K.M., Arnold R.L., McElhiney S.P., Shroff K.E., Pachuk C.J. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J. Infect. Dis. 182:2000;1311-1320.
49. Domingo C., Pardeiro M., Castilla C.et al. In vitro and in vivo immunological properties of a recombinant herpes simplex virus type 2 gD-gB chimaeric protein. J. Clin. Virol. 18:2000;240.
50. Pereira L. Domain structure of HSV-1 gB: neutralizing epitopes map in regions of continuous and discontinous residues. Virology. 172:1989;11-24.
51. Pellet P.E., Kosoulas K.J., Pereira L., Roizman B. Anatomy of the herpes simples virus type 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants. J. Virol. 53:1985;243-253.
52. Chapsal J.M., Pereira L. Characterization of epitopes on native and denatured forms of herpes simpolex virus glycoprotein B. J. Virol. 164:1988;427-434.
53. Isola V.J., Eisenberg R.J., Siebert G.R., Heilman C.J., Wilcox W.C., Cohen G.H. Fine mapping of antigenic site II of herpes simplex glycoprotein D. J. Virol. 63:1989;2325-2334.
54. Hanke T., Graham F.L., Rosenthal K.L., Johnson D.C. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus and synthetic peptides. J. Virol. 65:1991;1177-1186.
55. Welling-Webster S., Scheffer A.J., Welling G.W. B and T cell epitopes of glycoprotein D of herpes simplex type 1. FEMS Microbiol. Immunol. 3:1991;59-68.
56. Witmer L.A., Rosenthal K.L., Graham F.L., Fiedman H.M., Yee A., Johnson D.C. Cytotoxic T lymphocytes specific for herpes simplex (HSV) studied using adenovirus vectors expressing HSV glycoproteins. J. Gen. Virol. 71:1990;387-396.
57. Wyckoff J.H., Osmand A.P., Eisenberg R.J., Cohen G.H., Rouse B.T. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex type 1 gD. Immunobiology. 177:1988;134-148.
58. Muggeridge M.I., Chiang H.Y., Cohen G.H., Eisenberg R.J. Mapping of a functional site on herpes simplex type glycoprotein gD. J. Cell Biochem. 16C(Suppl):1992;132.
59. Flynn D.C., Meyer W.J., Mackenzie J.M. Jr., Johnston R.E. A conformational change in Sindbis virus glycoproteins E1 and E2 is detected at the plasma membrane as a consequence of early virus-cell interaction. J. Virol. 64:1990;3643-3653.
60. Weis JH, Enquist LW, Salstrom JS, Watson RJ. An immunologically chimaeric protein containing herpes simples virus type 1 glycoprotein D. Nature 1983;302:72-4.
61. Norais N., Tang D., Kaur S., Chamberlain S.H., Masiarz F.R., Burke R.L. et al. Disulfide bonds of herpes simples virus type 2 glycoprotein gB. J. Virol. 70:1996;7379-7387.
62. Bradley L.M., Yoshimoto K., Swain S.L. The cytokines IL-4, IFN-γ, and IL-12 regulate the development of subsets of memory effector helper T-cells in vitro. J. Immunol. 155:1995;1713.
63. Maggi E., Paronchi P., Manetti R.et al. Reciprocal regulatory effects of IFN-γ and IL-4 on the in vitro development of human Th1 and Th2 clones. J. Immunol. 148:1992;2142-2147.
64. Ho M. Interferon as an agent against HSV. J. Invest. Dermatol. 95:1990;158-160.
65. Smith P.M., Wolcott R.M., Chervenak R., Jennings S.R. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-γ (IFN-γ). Virology. 202:1994;76-88.
66. Krieg A.M., Yi A.-K., Matson S., Waldschmidt T.J.et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
67. Sato Y., Roman M., Tighe H. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
68. Lewis P.J., Van Drunen Littel-van den Hurk S., Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J. Virol. 73:1999;10214-10223.
69. Rupinderderjeet K., Geetanjali S., Sudhanshu V. Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protei. J. Infect. Dis. 185:2002;1-12.